Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Arctic Bioscience Regulatory Filings 2025

Aug 18, 2025

3536_rns_2025-08-18_1c950e30-1955-4d73-b75f-6a596407db3e.html

Regulatory Filings

Open in viewer

Opens in your device viewer

Arctic Bioscience - Achieves significant vision improvement in Clinical Glaucoma Study

Arctic Bioscience - Achieves significant vision improvement in Clinical Glaucoma Study

Arctic Bioscience today announced that a clinical study published

in International Ophthalmology demonstrated that daily supplementation with

ROMEGA® herring caviar oil resulted in a statistically significant improvement

in the visual field measure Mean Deviation (MD) in patients with primary open

-angle glaucoma (POAG) and controlled intraocular pressure (IOP). No adverse

events were observed, and the treatment was well tolerated.

About the study

The three-month study included 50 patients. The intervention group received one

ROMEGA® capsule (500mg) daily. Results showed a clear improvement in MD values

in the intervention group (p = 0.01) compared to baseline, while no similar

improvement was observed in the control group. Best-corrected visual acuity and

retinal nerve fiber layer thickness remained stable, and intraocular pressure

was maintained.

Next steps

"These findings suggest that ROMEGA® may be a safe and potentially effective

adjunct to protect vision in glaucoma patients, even when IOP is already

controlled. We are now planning larger, randomized studies to confirm these

promising results", says Hogne Hallaråker, CSO in Arctic Bioscience.

Link for more info: https://pmc.ncbi.nlm.nih.gov/articles/PMC12279572/

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: [email protected]

Hogne Hallaråker

CSO

Phone: +47 481 20 388

E-mail: [email protected]

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.